Efficacy and safety of bevacizumab combined with regimen of pemetrexed/cisplatin as the first-line therapy for advanced lung adenocarcinoma patients with EGFR wild-type

ZHANG Qian; WANG Wei; XU Chunhua

doi:10.3969/j.issn.1009-0460.2019.04.015

Home>Articles>Efficacy and safety of bevacizumab combined with regimen of pemetrexed/cisplatin as the first-line therapy for advanced lung adenocarcinoma patients with EGFR wild-type

DOI: 10.3969/j.issn.1009-0460.2019.04.015

Efficacy and safety of bevacizumab combined with regimen of pemetrexed/cisplatin as the first-line therapy for advanced lung adenocarcinoma patients with EGFR wild-type

ZHANG Qian

WANG Wei

XU Chunhua

Machine-generated Keywords：

Publication Date：2019-01-01

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：5( 359-363 )

Chinese Clinical Oncology

PKUISTIC

ISSN：1009-0460

Year, Vol.(Issue)：2019,24(4)